Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1FED 1

Study Type

Interventional 2Observational 1

Sponsor

Conditions

Neoplasms 2Tuberous Sclerosis 1Tourette Syndrome 1Tic Disorders 1Pain 1Neurodevelopmental Disorders 1Mental Disorders 1Fragile X Syndrome 1DiGeorge Syndrome 1Depressive Disorder 1Depression 1Caregiver Burden 1Autistic Disorder 1Autism Spectrum Disorder 1Attention Deficit Disorder with Hyperactivity 1Anxiety Disorders 122q11 Deletion Syndrome 1

Interventions

Cisplatin 3193Cyclophosphamide 3187Carboplatin 2968Radiotherapy 2784Paclitaxel 2716Gemcitabine 2569pembrolizumab 2378Bevacizumab 2206Docetaxel 2196Fluorouracil 1848Capecitabine 1828Oxaliplatin 1738Dexamethasone 1604Nivolumab 1580Doxorubicin 1501Rituximab 1487Magnetic Resonance Spectroscopy 1382Etoposide 1345Irinotecan 1245Leucovorin 1222Drug Therapy 1202Cytarabine 1130Pemetrexed 1074fludarabine 1056Specimen Handling 1009Vincristine 964Cetuximab 943Prednisone 940Trastuzumab 940Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Selective Serotonin Reuptake Inhibitors × Clear all
NCT06081348 2025-07-16

CALM

Holland Bloorview Kids Rehabilitation Hospital

Phase 2 Recruiting
130 enrolled

Autism Spectrum Disorder, Anxiety Disorders, Attention Deficit Disorder with Hyperactivity, Autistic Disorder, DiGeorge Syndrome, Fragile X Syndrome, Tourette Syndrome, Tic Disorders, Tuberous Sclerosis, 22q11 Deletion Syndrome, Neurodevelopmental Disorders

NCT01077596 2017-05-30

Carcinogenicity Study of Bupropion

GlaxoSmithKline

Completed
50,430 enrolled 23 charts

Depressive Disorder, Neoplasms

NCT00129467 2015-04-24

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

VA Office of Research and Development

Phase NA Completed
47 enrolled 13 charts

Caregiver Burden, Mental Disorders, Depression, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡